Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10

Maier, Milligan, Sloane, Langer, Cruz, Chacur Marucia, Spataro Leah, Wieseler-Frank Julie, Hammack, Flotte, Forsayeth, Leinwand, Chavez Raymond, Watkins

Description

Despite many decades of drug development, effective therapies for neuropathic pain remain elusive. The recent recognition of spinal cord glia and glial pro-inflammatory cytokines as important contributors to neuropathic pain suggests an alternative therapeutic strategy; that is, targeting glial activation or its downstream consequences. While several glial-selective drugs have been successful in controlling neuropathic pain in animal models, none are optimal for human use. Thus the aim of the present studies was to explore a novel approach for controlling neuropathic pain. Here, an adeno-associated viral (serotype II; AAV2) vector was created that encodes the anti-inflammatory cytokine, interleukin-10 (IL-10). This anti-inflammatory cytokine is known to suppress the production of pro-inflammatory cytokines. Upon intrathecal administration, this novel AAV2-IL-10 vector was successful in transiently preventing and reversing neuropathic pain. Intrathecal administration of an AAV2 vector encoding beta-galactosidase revealed that AAV2 preferentially infects meningeal cells surrounding the CSF space. Taken together, these data provide initial support that intrathecal gene therapy to drive the production of IL-10 may prove to be an efficacious treatment for neuropathic pain.

Informations

• Publié par: biomed
• Publié le: 01 janvier 2005
• Nombre de lectures: 0
• Langue: English

Extrait

Pga e 1fo1  ( 3 apegum nr bet nor foaticnoitrup esops)

Published: 25 February 2005 Received: 15 January 2005 Acc Molecular Pain 2005, 1 :9 doi:10.1186/1744-8069-1-9  epted: 25 February 2005 This article is available from: http ://www.molecularpain.com/content/1/1/9 © 2005 Milligan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons. org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the orig inal work is properly cited.

Molecular Pain

Address: 1 Department of Psychology & the Center for Neuroscience, University of CO at Boulder, Boulder, CO 80309 USA, 2 Department of Molecular, Cellular & Developmenta l Biology, University of CO at Boulder, Boulder, CO 80309 USA, 3 Genetics Institute, the Powell Gene Therapy Center & Department of Pediatrics, University of FL at Gainesville, Gainesville, FL 32610 USA and 4 Avigen, Inc., Alameda, CA 94502 USA Email: Erin D Milligan - [e-mail]. edu; Evan M Sloane - [e-mail]; Stephen J Langer - [e-mail]; Pedro E Cruz - pec [e-mail]; Marucia Chacur - [e-mail]; Leah Spataro - [e-mail]; Juli e Wieseler-Frank - [e-mail]; Sayamwong E Hammack - [e-mail]; St even F Maier - smaier@psych. Colorado.edu; Terence R Flotte - [e-mail]; John R Forsayeth - [e-mail]; Leslie A Leinwand - [e-mail]; Raymond Chavez - [e-mail]; Linda R Watkins* - [e-mail] * Corresponding author

Research Open Access Controlling neuropathic pain by ad eno-associated virus driven production of the anti-inf lammatory cytokine, interleukin-10 Erin D Milligan 1 , Evan M Sloane 1 , Stephen J Langer 2 , Pedro E Cruz 3 , Marucia Chacur 1 , Leah Spataro 1 , Julie Wieseler-Frank 1 , Sayamwong E Hammack 1 , Steven F Maier 1 , Terence R Flotte 3 , John R Forsayeth 4 , Leslie A Leinwand 2 , Raymond Chavez 4 and Linda R Watkins* 1

Bio Med  Central

Background successfully resolve such pain [1-3]. To date, drug thera- Neuropathic pain is an especially difficult chronic pain pies developed for human neuropathic pain have targeted syndrome to treat. No compounds are yet available that neurons. However, evidence has recently accumulated

Abstract Despite many decades of drug development, e ffective therapies for neuropathic pain remain elusive. The recent recognition of spinal cord gl ia and glial pro-inflammato ry cytokines as important contributors to neuropathic pain suggests an altern ative therapeutic strategy; that is, targeting glial activation or its downstream cons equences. While several glial-sele ctive drugs have been successful in controlling neuropathic pain in animal models , none are optimal for human use. Thus the aim of the present studies was to explore a novel appr oach for controlling neuropathic pain. Here, an adeno-associated viral (serotype II; AAV2) vector was created that encodes the anti-inflammatory cytokine, interleukin-10 (IL-10). This anti-inflammatory cyto kine is known to suppress the production of pro-inflammatory cytokines. Upon intrathecal admini stration, this novel AAV2-IL-10 vector was successful in transiently preventing and reversing neuropathic pain. Intrathecal administration of an AAV2 vecto r encoding beta-galacto sidase revealed that AAV2 preferentially infects meningeal cells surrounding the CSF spac e. Taken together, these data provide initial support that intrathecal gene therapy to driv e the production of IL-10 may prove to be an efficacious treatment for neuropathic pain.